Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy

JACC Heart Failure(2021)10.1016/j.jchf.2021.01.011Source: DataRank Database

Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy is a research paper published in JACC Heart Failure (2021). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

43 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 3.80)OA: bronzeTopics (39)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Brian Claggett ORCID,Margaret M. Redfield ORCID,Sanjiv J. Shah ORCID,Inder S. Anand ORCID,Felipe A. Martínez ORCID

Live enrichment

PubMed:33714741 OpenAlex:https://openalex.org/W3139094174

National Institutes of Health

Grant: 5-T32 HL007604

NHLBI NIH HHS

Grant: T32 HL007604

AstraZeneca

Gilead Sciences

United Therapeutics Corporation

Cytokinetics

Novartis

Pfizer

Sanofi Pasteur

Amgen

Eisai

National Heart, Lung, and Blood Institute

Respicardia

Daiichi-Sankyo

GlaxoSmithKline

FWCI

3.80

Citation Percentile

0.9%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.sciencedirect.com/science/article/pii/S2213177921000597/pdf

BRONZEhttps://www.sciencedirect.com/science/article/pii/S2213177921000597/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2213177921000597/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2213177921000597?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213177921000597?httpAccept=text/plain

Fields of Study

Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac pacing and defibrillation studiesMedicineAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsFemaleHeart FailureHumansPrognosisProspective StudiesStroke Volume

MeSH Terms

Angiotensin-Converting Enzyme InhibitorsFemaleHeart FailureHumansPrognosisProspective StudiesStroke VolumeAngiotensin Receptor Antagonists

Keywords

MedicineHeart failureInternal medicineCardiologyValsartanSacubitrilPresyncopeEjection fractionPeripheral edemaHeart failure with preserved ejection fractionVital signsProspective cohort studyBlood pressureHeart rateSurgeryAdverse effectCongestionSacubitril/valsartanHeart Failure Signs And Symptoms

Sustainable Development Goals

SDG 0: Good health and well-being

Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy

FAIR Checklist

Authors (14)

Funding (15 grants)

Impact

Open Access

Topics